Non-invasive detection of early-stage lung cancer through exhaled breath volatile organic compound analysis

Abstract

Exhaled breath analysis is an emerging non-invasive diagnostic approach that analyses the complex mixture of volatile organic compounds (VOCs) present in human breath to provide insights into a person's metabolic state. This technique is based on the premise that metabolic processes in the body produce various VOCs that can be altered in the presence of disease, reflecting changes at the cellular and systemic levels.1,2 Breath analysis has emerged significant interest in the medical community due to its noninvasiveness, ease of collection, and the potential to offer rapid, real-time diagnostic information without the need for more invasive procedures like biopsies or blood draws. Breath analysis is applied in a wide range of diseases, exploiting the unique VOC profiles associated with different pathological conditions. For instance, in respiratory diseases such as asthma, chronic obstructive pulmonary disease, and lung infections, distinct VOC patterns have been identified that correlate with disease severity and patient outcomes.3 In metabolic disorders like diabetes, breath acetone levels have been studied as a marker for blood glucose monitoring. Similarly, gastrointestinal diseases such as Helicobacter pylori infection are detectable through specific breath biomarkers like ammonia. Moreover, in liver disease, elevated levels of VOCs such as dimethyl sulfide and other sulfur-containing compounds have been linked to hepatic dysfunction. One of the most promising applications of breath analysis is in the field of oncology. Cancer cells exhibit altered metabolism, often leading to the production of distinct VOCs that can be detected in exhaled breath.4 This principle has been applied in the detection of various cancers, including lung, breast, colorectal, and ovarian cancers, demonstrating the potential of breath analysis as a non-invasive cancer screening tool. The VOC production in cancerous tissues is closely linked to the unique metabolic and biochemical alterations associated with tumorigenesis. In lung cancer, cancer cells undergo significant metabolic reprogramming, which includes increased glycolysis, altered lipid metabolism, and elevated oxidative stress. These changes lead to the production of various reactive oxygen species, thereby generates volatile alkanes and aldehydes, such as pentane, isoprene, and hexanal, commonly detected in the breath of lung cancer patients. Enhanced anaerobic glycolysis in cancer cells increases the release of ketones, including acetone, as by-products of altered carbohydrate metabolism. Together, these biochemical pathways contribute to a distinct VOC profile in cancer patients, providing a non-invasive means to potentially detect metabolic changes specific to malignant tissues. The non-invasive nature of breath analysis, coupled with its potential for early detection and continuous monitoring, makes it an attractive option for cancer diagnostics. The general diagram of exhaled breath VOC analysis for lung cancer detection is depicted in Figure 1. This perspective explores the potential of exhaled breath analysis in the screening of early-stage cancer, highlighting the techniques of breath analysis, clinical evidence and validation, challenges, and future directions.Figure 1: Human exhaled breath VOC analysis.UV: Ultraviolet; VOC: volatile organic compound.Exhaled breath analysis in lung cancer screening: Exhaled breath analysis is emerging as a promising diagnostic tool for the early detection and monitoring of lung cancer, particularly early-stage cancers. Lung cancer is a significant global health issue with high morbidity and mortality rates, largely due to late diagnosis when the disease is often at an advanced stage.5 Traditional diagnostic methods, such as visual examinations, biopsies, and imaging, frequently fail to identify the disease early when it is more treatable. Therefore, there is a critical need for noninvasive, rapid, and cost-effective screening tools to improve early detection and clinical outcomes. Breath analysis offers a novel approach by targeting the metabolic alterations associated with lung cancer. Cancer cells exhibit altered metabolic pathways, leading to the production of specific VOCs that can be detected in exhaled breath. In lung cancer, these changes are primarily driven by increased oxidative stress, inflammation, and lipid peroxidation, resulting in elevated levels of VOCs such as alkanes, aldehydes, ketones, and alcohols. For example, increased levels of pentane and hexanal are associated with oxidative stress, while higher concentrations of acetone may reflect altered carbohydrate metabolism. These VOCs form a distinct metabolic fingerprint of cancerous tissues, offering a noninvasive method for screening and diagnosis. Studies have identified specific VOCs in the breath of lung cancer patients, including elevated levels of alkanes, aldehydes, and other organic compounds indicative of the disease. These VOCs serve as potential biomarkers for early detection, helping to differentiate between malignant and benign conditions, as well as between various stages of the disease.6 To advance the clinical applicability of exhaled breath analysis for lung cancer detection, Extensive validation of specific VOC biomarkers across diverse populations is essential. Current studies have limitations, with biomarker profiles potentially varying based on genetic, environmental, and lifestyle factors unique to different demographic groups. Larger, multicenter trials are required for establishing the consistency and reliability of these biomarkers across diverse populations, thereby enabling breath analysis as a diagnostic tool for lung cancer detection. Techniques for breath analysis in lung cancer screening: Exhaled breath analysis relies on various analytical techniques to identify and quantify VOCs associated with lung cancer. Among these, gas chromatography-mass spectrometry is considered the gold standard due to its high sensitivity and specificity in detecting a wide range of VOCs.7 Gas chromatography-mass spectrometry allows for detailed profiling of breath samples, providing comprehensive insights into the complex mixture of compounds present, which is crucial for identifying specific biomarkers linked to lung cancer. Proton transfer reaction-mass spectrometry offers another powerful approach, providing real-time analysis of VOCs with excellent sensitivity. This capability makes proton transfer reaction- mass spectrometry particularly useful for rapid screening applications, where immediate results are desirable. Electronic nose (e-nose) technology, which employs sensor arrays to detect patterns of VOCs, also holds promise in the screening of lung cancer. We have utilized a self-developed e-nose device to discriminate cancer from controls and have also identified elevated levels of VOCs, such as isobutene, carbon monoxide, propane, ethanol, acetone, and ammonia, in lung cancer patients.8,9 The e-nose is advantageous for its accessibility and cost–effectiveness, making it suitable for large-scale screening initiatives. Compared to traditional diagnostic methods such as computed tomography imaging and biopsies, breath analysis offers potential cost advantages through its non-invasive nature, rapid sample collection, and the ability to perform high-throughput screening in primary care settings. The operational and equipment costs associated with e-nose techniques is less in comparison with other methods. The implementation of breath analysis may lead to significant cost savings by facilitating early diagnosis, which is often associated with better patient outcomes and lower long-term treatment costs. To substantiate these potential benefits, future studies should include detailed cost-benefit analyses comparing breath analysis with existing diagnostic modalities. However, while e-nose technology can effectively differentiate between healthy individuals and those with lung cancer, it typically offers less detailed chemical information compared to gas chromatography-mass spectrometry.7,8 Each of these methods has unique strengths in terms of sensitivity, specificity, and the ability to handle complex VOC patterns, contributing to the overall potential of exhaled breath analysis as a noninvasive diagnostic tool. As research advances, the development of standardized protocols and further refinement of these analytical techniques will be essential to fully harness their clinical potential, ultimately improving early detection and patient outcomes in lung cancer. Clinical evidence and validation: Several studies have demonstrated the potential of exhaled breath analysis in the screening of lung cancer. Additional Table 1 shows the studies on lung cancer detection through exhaled breath analysis. Clinical trials and pilot studies have identified specific VOCs that are significantly elevated in the breath of lung cancer patients compared to healthy controls or individuals with benign conditions. For example, research has highlighted the presence of increased levels of ethanol, acetaldehyde, and 2-butanone in the breath of lung cancer patients.2 Furthermore, breath analysis has shown promise in distinguishing between different stages of lung cancer, potentially allowing for the stratification of patients based on disease severity. In our studies, we have employed a metal oxide semiconductor- based e-nose to accurately differentiate between lung cancer stages, as well as distinguish patients from controls and patients with other respiratory diseases.3,6,9,10 However, while the initial results are promising, there remains a need for larger, multicenter studies to validate these findings and establish standardized protocols for breath sampling, analysis, and interpretation. Factors such as diet, medication, and environmental exposures can influence breath VOC profiles, necessitating the development of robust methods to account for these variables.11,12 In most of the studies, these factors are addressed by implementing pre-sampling protocols, such as fasting periods or dietary restrictions, prior to breath collection and the sample collection in a controlled room.6,8-10 Additionally, participants are often instructed to avoid specific medications and limit exposure to pollutants before sampling to reduce external VOC interference. Standardized questionnaires on recent dietary intake, medication use, and environmental exposures, could enhance consistency in future research. The application of exhaled breath analysis in lung cancer screening offers several advantages. It is noninvasive, painless, and requires minimal patient compliance, making it suitable for repeated measurements and longitudinal monitoring. Additionally, breath analysis can be conducted rapidly and at a relatively low cost, making it an attractive option for mass screening in high-risk populations. Challenges and future perspectives: Challenges remain in the standardization of breath collection and analysis techniques, as well as in the identification of universally reliable biomarkers for lung cancer. Future research in this area should focus on the optimization of analytical techniques, the identification of robust and specific VOC biomarkers, and the integration of breath analysis with other diagnostic modalities, such as imaging and genomic profiling, to enhance diagnostic accuracy by combining metabolic signatures with anatomical and genetic information. Breath VOC patterns could be used as a preliminary screening method to identify high-risk individuals who would benefit from confirmatory imaging scans, or to guide further genomic testing in cases where breath analysis indicates potential malignancy. The development of portable and user-friendly devices, such as handheld e-noses, could further facilitate the adoption of breath analysis in clinical settings and community-based screening programs. Exhaled breath analysis holds significant promise as a noninvasive screening tool for lung cancer. By providing insights into the metabolic changes associated with the disease, breath analysis could enable earlier detection and more personalized approaches to patient management, ultimately improving outcomes for individuals affected by this challenging condition.

Topics & Concepts